Trial challenges standard care: skip the middle step for better UC control?
NCT ID NCT07235904
Summary
This study is testing if starting treatment with a newer injectable biologic drug (mirikizumab) right away leads to better long-term disease control for people newly diagnosed with moderate-to-severe ulcerative colitis. It compares this 'top-down' approach to the current standard, which starts with an older pill medication (azathioprine). About 300 participants will be randomly assigned to one of the two treatment groups and followed for one year to see which approach works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Schleswig-Holstein
RECRUITINGKiel, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.